{"name":"BRIM Biotechnology Inc.","slug":"brim-biotechnology-inc","ticker":"","exchange":"","domain":"","description":"BRIM Biotechnology Inc. is a clinical-stage biotechnology company focused on developing innovative ophthalmic solutions. The company has a pipeline of five drug candidates, with BRM421 Ophthalmic Solution in Phase 3 trials and BRM424 Ophthalmic Solution in Phase 2.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"BRM421","genericName":"BRM421","slug":"brm421","indication":"Other","status":"phase_2"},{"name":"BRM421 Ophthalmic Solution, 0.03%","genericName":"BRM421 Ophthalmic Solution, 0.03%","slug":"brm421-ophthalmic-solution-0-03","indication":"Other","status":"phase_2"},{"name":"BRM421 Ophthalmic Solution, 0.06%","genericName":"BRM421 Ophthalmic Solution, 0.06%","slug":"brm421-ophthalmic-solution-0-06","indication":"Other","status":"phase_2"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"BRM421 Ophthalmic Solution","genericName":"BRM421 Ophthalmic Solution","slug":"brm421-ophthalmic-solution","indication":"Dry eye disease or ocular surface disease (presumed, based on ophthalmic formulation)","status":"phase_3"},{"name":"BRM424 Ophthalmic Solution - Dose1","genericName":"BRM424 Ophthalmic Solution - Dose1","slug":"brm424-ophthalmic-solution-dose1","indication":"Treatment of dry eye disease","status":"phase_2"}]}],"pipeline":[{"name":"BRM421","genericName":"BRM421","slug":"brm421","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BRM421 Ophthalmic Solution","genericName":"BRM421 Ophthalmic Solution","slug":"brm421-ophthalmic-solution","phase":"phase_3","mechanism":"BRM421 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms.","indications":["Dry eye disease or ocular surface disease (presumed, based on ophthalmic formulation)"],"catalyst":""},{"name":"BRM424 Ophthalmic Solution - Dose1","genericName":"BRM424 Ophthalmic Solution - Dose1","slug":"brm424-ophthalmic-solution-dose1","phase":"phase_2","mechanism":"BRM424 Ophthalmic Solution is a topical anti-inflammatory agent.","indications":["Treatment of dry eye disease"],"catalyst":""},{"name":"BRM421 Ophthalmic Solution, 0.03%","genericName":"BRM421 Ophthalmic Solution, 0.03%","slug":"brm421-ophthalmic-solution-0-03","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BRM421 Ophthalmic Solution, 0.06%","genericName":"BRM421 Ophthalmic Solution, 0.06%","slug":"brm421-ophthalmic-solution-0-06","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"pipeline","source":"GuruFocus","summary":"Stock List: Research Stocks from Around the World - GuruFocus","headline":"Stock List: Research Stocks from Around the World","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNT0prd1BWcGg4OE00QXpzS2RDMWdmSzAyek5VelE3bkJvRFQ1SndVa1doQXhnVzY1Q2x2UEx6N2pLY1pZaFptMm1GQTRwMFZXQ0xXYngtYy1YV2l5WWJGRDVYMGZjdmZ0TGNxQjluX1NGaFBzOXgyUW9WYmVWakRXTENha1FZaGdYZmh2OG1NNnBOZlo3Z20xNA?oc=5","date":"2026-04-02","type":"pipeline","source":"openPR.com","summary":"Neurotrophic Keratopathy Market: High-Growth Opportunities for Investors to 2034 - DelveInsight - openPR.com","headline":"Neurotrophic Keratopathy Market: High-Growth Opportunities for Investors to 2034 - DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOQ3dMUDJWMENrZjdsdVVUMWoyX2dCbzZPd01EMmVNdHdoMERlb05Hdk9UZWNwWXlLbTRXMzBPU0FMX3FuZXhKRUEzNmJsSTRSYjhObnJLR1VPMHRjMzlGV1BzV3JXZkVOS2hIdHU3alUwYmZGNUtZZFNfdkw0Y2tud21WOVBScGlUekxXQkllajRWMzFuOGJUTllWcVpqS05zdmZ3QXBkYmU4NjBGUDVtelJZYzRfT3BWTFQ0RnhPb0V5QWRTeFh5c0RaVmRLU2JyLTBmaW5xaDdiSWpGWk9tZ2c0MmJhMVI2VTFXam5WNGlGUG5NMVB3QXI4WXVIS2ZfNkQxZXRwc3EzQnFFbDQ5MDk4dnZqb1pOZEswTkI5c1RDRl9KLUc1Um1SaURSX2RKNEE?oc=5","date":"2026-02-02","type":"pipeline","source":"GlobeNewswire","summary":"Limbal Stem Cell Deficiency Market Set to Transform During - GlobeNewswire","headline":"Limbal Stem Cell Deficiency Market Set to Transform During","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxPNENwZFNOUy00TGpWSmJHbWV1V2UwQU5QWjAyd2owSUdlcWV2aThqZDktLXdJLVJubmVIMFQtal8zRlgxTEY2T1U0eWFYU2d3enMwMXdYaHN4NjZKSGxOTTRTdzRXX2tFVzZOSlFLYW5ZOTE2Y1FIcXB5dFhFd2ZfdS1jdDRXVUpvTG1mUjZrYk9tcFIzbGl3YWVWZV90T3EwZ1pSeEVRdWhVT0dOb1JMZnMzMGJ1VVhWeUVxdG1hRGVia04zNnZGVTRKQUUxU3FRN0dFRGtHejlKRnJmMEx4R2x5Xzc1QVAyNS16R1A3WkFxR1VvZHdyUTREWnJYa2h2cUJlUVVmN29XMFVxZWk0MEtUdTlSWGs3Y0VNdnNCMXNCOUlieDZyTHgtX2FpYnJBN1E?oc=5","date":"2025-07-14","type":"pipeline","source":"PR Newswire","summary":"MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight - PR Newswire","headline":"MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTlueFcxMloxdHhmMklNRmVicU9oc1hZMkY1dElEeUNUeWJTdmV2YzJycktUNG1STmthZ1FOLXBweTM4WTZCZVF4TXc3VHVXS01rdUhfMXVUZmp4N3VBQUR5RkI2M2Q3b1pGaGNzeG5OZDF1YmdHWFZVQkkyMS1HTV9zMG96WEluMk12MU5XaEVWWHhhZXpmZ19Fd2pSelNuN0FoVXozMERsVHd0YnJVdlYyb1d1LTNJU1NQdWItM3hxZ3RlZ01mcw?oc=5","date":"2025-01-28","type":"pipeline","source":"PR Newswire","summary":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - PR Newswire","headline":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-03","type":"pipeline","source":"GlobeNewswire","summary":"Dry Eye Products Market Opportunities and Strategies to - GlobeNewswire","headline":"Dry Eye Products Market Opportunities and Strategies to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOX1dWZF9URmh1SkxWdGpJSnZfUXU4eF8xOUdsa0Y2SEZNdGRxR2RfaDYxSEllNzdfcDFKaUhWTnFNZXQ0LTZieVhOT3MwelNuWHRjX1BWZ0dHVzhXc1U1bWFoUndmbjlnUXR6RDZud1VSMWJOWHozLXA0R09ZUG1YWUozRXdsVENTUWZic293UXJMMFhoY1QwLUI1OGJ4eFVPX3VKbDFZOWFPdzhwZzhvOGVsWlZfa2c?oc=5","date":"2023-04-11","type":"trial","source":"Eyes On Eyecare","summary":"BRIM Biotechnology submits IND for neurotrophic keratitis study - Eyes On Eyecare","headline":"BRIM Biotechnology submits IND for neurotrophic keratitis study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPSUl4TVcxMVdrMk9OaUVWSkt5cy1Pa0tYajJqek5tSDMteHRPYmpkZUZaS1hhcGcyel9nUjN3Vi1qMWl6ZWRwbXhGbE1tRWV3akRyNkR4SlVOUkRiVm1YaGtMNjZEVksyU3d0Qm1yVE1VYVN3dUg2VmU1RThIeTNkWDRYMjQ5MHE1T29HcU56bG8wLVhkb1Z6WDlNcVkzRTR3VTd2TXI4OEROb2t5X3ZrLUJzTGY?oc=5","date":"2023-04-10","type":"trial","source":"Ophthalmology Times","summary":"BRIM submits IND for BRIM424 phase 2 study treating neurotrophic keratitis - Ophthalmology Times","headline":"BRIM submits IND for BRIM424 phase 2 study treating neurotrophic keratitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNOS1Tem91Zld2c0JDSXd6OG1yVlRhNDA1bTB0Z2VmRFF3N0dVSkRNWktBQWlrekJvV1R1TVVvdGtSZ3JSdTBuUUxpc3RuMGhJTzZPTlhOSjFBaGsyd3FwZEdsTDVFU3hqZWdpa01OaXA1V0lGbGtlU0lvamVsT2Q2eDNCUExVOVFxOTRTM2ZrdEFjY1lUN0h6X2gteTdtM1RTRWFlRDEtcFJyRVNKWVJZ?oc=5","date":"2022-08-31","type":"trial","source":"BioWorld News","summary":"Brim Biotech announces $18M raise to advance dry eye drug to phase III - BioWorld News","headline":"Brim Biotech announces $18M raise to advance dry eye drug to phase III","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE1KOUhRM3V2blZwUHY1SWVEYnJuWV9FTUxBbTdVZmFZLWgzVU9jbEh5U2pWcmc0WUliZFpyeHdXREtUVjhkdlJJSVhTR1FqUXhSdUM3Wmw3ZnhzTWs4WnY2bXZIRk1kb3BFazc4?oc=5","date":"2022-06-23","type":"pipeline","source":"Labiotech.eu","summary":"BRIM Biotechnology enters OTC trading in Taiwan - Labiotech.eu","headline":"BRIM Biotechnology enters OTC trading in Taiwan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQcmhDaDVaaTYwNHFxSmVaejRxb2RzNDIwbU4yX3Rxemd4M0twMW5JOVNWd3RBZGZhYUFjM05VOXZ4b29kdGp2SUVka2U4LTRQREhsYUw2VkprTTlzSUMzTDZrYlhwVUJVaEF2Y1E5T3R3S2swdUJUTm12UkNFWHNoOUlIRUZ1bjRFNDh2dlNiQTlwNEdnbDllZHVHYlV4T0JULXBENUd1dzF6cmJ5c0JTZmdlRkhfTG1WQ1RHNFdTbExndEk?oc=5","date":"2018-07-09","type":"pipeline","source":"GlobeNewswire","summary":"About Pharmagreen Biotech Inc. and WFS Pharmagreen Inc. - GlobeNewswire","headline":"About Pharmagreen Biotech Inc. and WFS Pharmagreen Inc.","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":4,"phase_3":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}